IMP [BUY +39.6%] - Sales growth to regain pace post COVID-19 disruptions - Update
  • 28 Jan 2021
  • Company Research
We reiterate BUY as we believe IMP’s leading production technology and ample spare capacity — along with a Government policy backdrop that favors high-quality, locally produced drugs in the hospital channel — will lead to elevated earnings growth in the n